Biotech

The U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Eli Lilly and Co.’s (NYSE:LLY) Kisunla (donanemab-azbt) once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer’s disease (AD). The FDA...

Merck & Co. Inc. (NYSE:MRK) agreed on Wednesday to acquire Verona Pharma plc (NASDAQ:VRNA) for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ADS represents eight ordinary shares of Verona Pharma. Through the acquisition of this...

RxSight Inc. (NASDAQ:RXST) plummeted by 34.32% in after-hours trading on Tuesday. The drop followed the company’s decision to revise its 2025 revenue forecast. What Happened: The stock of RxSight Inc. experienced a sharp decline in after-hours trading, closing at $8.40, a 34.32% decrease from...

Calidi Biotherapeutics Inc. (NYSE:CLDI) stock surged by 39.47% in the after-hours trading session on Tuesday. The stock price increased by $0.095, reaching $0.34. The company’s stock had closed at $0.24 on the same day. What Happened: The stock’s after-hours surge comes on the heels of...

D. Boral Capital upgraded Artelo Biosciences, Inc. (NASDAQ:ARTL) on Tuesday. The analyst upgraded from Hold to Buy and introduced a price forecast of $20. Analyst Jason Kolbert wrote, “We continue to view Artelo as an emerging biotechnology company focused on Cachexia and chemotherapy-induced...

CARGO Therapeutics Inc. (NASDAQ:CRGX) saw its stock climb on Tuesday after the biotech firm announced a merger agreement with Concentra Biosciences LLC. Under the terms of the agreement, Concentra will acquire CARGO for $4.379 in cash per share, along with a non-transferable contingent value right...

On Monday, Cogent Biosciences, Inc. (NASDAQ:COGT) said bezuclastinib showed meaningful clinical benefit for patients with non-advanced systemic mastocytosis. The company said that its experimental drug reduced the symptoms of a chronic immune disorder called non-advanced systemic mastocytosis. The...

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) stock was trading higher on Tuesday, with a session volume of 160.9 million compared to the average volume of 4.03 million as per data from Benzinga Pro. What Happened ZyVersa Therapeutics provided regulatory and product support for FDA-authorized Emergency...

In a significant legal challenge that could reshape the future of public health policy in the United States, a powerful alliance of leading medical and public health organizations, including the American Academy of Pediatrics (AAP), the American College of Physicians (ACP), and the American Public...

Novo Nordisk A/S (NYSE:NVO) on Tuesday announced that it has submitted an application to the European Medicines Agency (EMA) for approval of a new, higher dose of its obesity treatment, Wegovy (subcutaneous semaglutide 7.2 mg). The submission is based on clinical data from the STEP UP and STEP UP...

Rallybio Corporation (NASDAQ:RLYB) agreed on Tuesday to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for hypophosphatasia (HPP), to joint venture partner Recursion Pharmaceuticals Inc. (NASDAQ:RXRX). The deal consideration of up to $25 million includes an upfront...

ProKidney Corp. (NASDAQ:PROK) stock is trading higher on Tuesday, with a session volume of 39.8 million compared to the average volume of 1.12 million as per data from Benzinga Pro. What happened: The chronic kidney disease (CKD)-focused company reported statistically significant and clinically...

Swissmedic, the Swiss Agency for Therapeutic Products, approved Novartis AG’s (NYSE:NVS) Coartem (artemether-lumefantrine) Baby on Tuesday. This marks the first malaria medicine specifically approved for newborns and young infants. The new treatment, also known as Riamet Baby in some...

Jasper Therapeutics, Inc. (NASDAQ:JSPR) stock is experiencing a steep decline on Monday, plummeting by nearly 55%. This significant drop is accompanied by an exceptionally high trading volume of 9.9 million shares, vastly exceeding its average daily volume of 251.9K, according to data from Benzinga...

Hims & Hers Health, Inc. (NYSE:HIMS) is currently experiencing a decline in its stock price, trading lower on Monday. The company’s stock has plummeted approximately 18% over the past month, reflecting recent challenges. A significant development contributing to this decline occurred in...